Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $180.00 short call and a strike $185.00 long call offers a potential 6.16% return on risk over the next 15 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $180.00 by expiration. The full premium credit of $0.29 would be kept by the premium seller. The risk of $4.71 would be incurred if the stock rose above the $185.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 27.04 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Pfizer Inc. Stock Is Boring, and That’s Perfect
Tue, 31 Oct 2017 14:36:41 +0000
Pfizer Inc. (NYSE:PFE) reported earnings this morning and PFE stock is down on the news. Pfizer beat on the bottom line and boosts guidance. The iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) has fallen 7% in about two weeks perhaps most influenced by combative remarks from President Trump vowing to continue fighting drug stocks and their management practices.
Amgen Inc. — Moody's assigns Baa1 to Amgen's notes; stable outlook
Tue, 31 Oct 2017 14:25:06 +0000
Rating Action: Moody's assigns Baa1 to Amgen's notes; stable outlook. Global Credit Research- 31 Oct 2017. New York, October 31, 2017– Moody's Investors Service assigned a Baa1 rating to the new senior …
Japan's Kirin cashes out of Amgen drug joint venture
Tue, 31 Oct 2017 08:59:25 +0000
Japan's Kirin Holdings Co Ltd <2503.T> said on Tuesday it would sell its share in a pharmaceutical research joint venture with California-based drugmaker Amgen Inc (AMGN.O) for $780 million. The joint venture, Kirin-Amgen, will buy the Japanese firm's 50 percent stake and will make further payments to Kirin for certain sales, the Japanese firm said in a statement, adding that the companies saw their collaboration as complete. Established in 1984 to fund the development of the kidney disease drug Epogen, the joint venture's scope grew to include, among others, the white blood cell-boosting drugs Neupogen and Neulasta, used during chemotherapy treatment, Amgen said in a separate statement.
Kirin-Amgen Joint Venture To Become Wholly-Owned Subsidiary Of Amgen
Tue, 31 Oct 2017 06:30:00 +0000
THOUSAND OAKS, Calif., Oct. 30, 2017 /PRNewswire/ — Amgen (AMGN) today announced that Amgen and Kirin Holdings (Kirin) have agreed that Kirin-Amgen, a joint venture between the two companies, will redeem Kirin's shares in the joint venture and, as a result, Kirin-Amgen will become a wholly-owned subsidiary of Amgen.
Amgen, Inc. :AMGN-US: Earnings Analysis: Q3, 2017 By the Numbers : October 30, 2017
Mon, 30 Oct 2017 14:14:39 +0000
Categories: Yahoo FinanceGet free summary analysis Amgen, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Amgen, Inc. – Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Celgene Corporation, Gilead Sciences, Inc., Biogen Inc., Alexion Pharmaceuticals, Inc., Abbott Laboratories and Johnson & Johnson (BMY-US, GSK-US, CELG-US, … Read more
(Read more…)
Related Posts
Also on Market Tamer…
Follow Us on Facebook